Yahoo Finance The Zacks Analyst Blog Highlights Amazon, Visa, Pfizer, Martin Marietta Materials and Zimmer Biomet
For Immediate Release
Chicago, IL – May 13, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. AMZN, Visa Inc. V, Pfizer Inc. PFE, Martin Marietta Materials, Inc. MLM and Zimmer Biomet Holdings, Inc. ZBH.
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Amazon, Visa and Pfizer
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., Visa Inc. and Pfizer Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Amazon have outperformed the Zacks Internet - Commerce industry over the year-to-date period (+24.7% vs. +17.2%). The company’s first quarter results were driven by Prime and AWS momentum. Strengthening AWS services portfolio and its growing adoption rate contributed well to AWS performance.
Ultrafast delivery services and expanding content portfolio were beneficial. Strengthening relationships with third-party sellers was a positive. Robust advertising business contributed well. Notably, improving Alexa skills along with robust smart home products offerings remain tailwinds.
Amazon’s expanding global presence remains a positive. Growing capabilities in grocery, pharmacy, healthcare and autonomous driving are other positives. Additionally, deepening focus on generative AI is a major plus. However, adverse macroeconomic challenges remain concerns.
(You can read the full research report on Amazon.com here >>>)
Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the year-to-date period (+7.6% vs. +5.4%). The company’s strategic acquisitions and alliances are fostering long-term growth and consistently driving its revenues. It expects net revenues to increase in low double digits for fiscal 2024.
Visa, fueled by increased payments, cross-border volumes and sustained investments in technology, is witnessing significant profit growth. It reported strong fiscal 2Q24 results. The ongoing shift to digital payments is advantageous for Visa, with strong domestic volumes supporting its overall performance.
A robust cash position enables the company to enhance shareholder value. However, elevated operating expenses pose margin challengesIt is witnessing a volatile cash volume from the Asia Pacific and CEMEA regions. Moreover, rising client incentives will affect its adjusted revenues.
(You can read the full research report on Visa here >>>)
Shares of Pfizer have gained +0.4% over the year-to-date period against the Zacks Large Cap Pharmaceuticals industry’s gain of +14.9%. The company beat first-quarter estimates for earnings but missed the same for sales. Pfizer’s top line is declining due to a steep drop in revenues from its COVID-19 products, the Comirnaty vaccine and Paxlovid oral pill, due to lower demand.
Concerns remain about its long-term growth drivers. Nonetheless, Pfizer expects better non-COVID operational revenue growth in the future quarters, driven by its in-line products like Vyndaqel and Prevnar, new launches like Abrysvo, Velsipity, Penbraya and newly acquired products, including those acquired from Seagen.
Huge profits from its COVID products strengthened its cash position. The funds are being used to make acquisitions, increase dividends, buy back shares and reduce debt.
(You can read the full research report on Pfizer here >>>)
Other noteworthy reports we are featuring today include Martin Marietta Materials, Inc. and Zimmer Biomet Holdings, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amazon.com, Inc. (AMZN) : Free Stock Analysis Report
Visa Inc. (V) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Martin Marietta Materials, Inc. (MLM) : Free Stock Analysis Report
Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report
